Your browser doesn't support javascript.
loading
Gastrointestinal symptoms and the severity of COVID-19: Disorders of gut-brain interaction are an outcome.
Ebrahim Nakhli, Ramin; Shanker, Aaron; Sarosiek, Irene; Boschman, Jeffrey; Espino, Karina; Sigaroodi, Solmaz; Al Bayati, Ihsan; Elhanafi, Sherif; Sadeghi, Amin; Sarosiek, Jerzy; Zuckerman, Marc J; Rezaie, Ali; McCallum, Richard W; Schmulson, Max J; Bashashati, Ali; Bashashati, Mohammad.
Afiliación
  • Ebrahim Nakhli R; School of Biomedical Engineering, University of British Columbia, Vancouver, British Columbia, Canada.
  • Shanker A; Division of Gastroenterology, Department of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA.
  • Sarosiek I; Division of Gastroenterology, Department of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA.
  • Boschman J; School of Biomedical Engineering, University of British Columbia, Vancouver, British Columbia, Canada.
  • Espino K; Division of Gastroenterology, Department of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA.
  • Sigaroodi S; Division of Gastroenterology, Department of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA.
  • Al Bayati I; Division of Gastroenterology, Department of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA.
  • Elhanafi S; Division of Gastroenterology, Department of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA.
  • Sadeghi A; Qatar Computing Research Institute, Hamad bin Khalifa University, Doha, Qatar.
  • Sarosiek J; Division of Gastroenterology, Department of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA.
  • Zuckerman MJ; Division of Gastroenterology, Department of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA.
  • Rezaie A; Division of Gastroenterology, Department of Medicine, GI Motility Program, Cedars-Sinai, Los Angeles, California, USA.
  • McCallum RW; Division of Gastroenterology, Department of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA.
  • Schmulson MJ; Laboratory of Liver, Pancreas and Motility (HIPAM), Unit of Research in Experimental Medicine, Faculty of Medicine-Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico.
  • Bashashati A; School of Biomedical Engineering, University of British Columbia, Vancouver, British Columbia, Canada.
  • Bashashati M; Department of Pathology and Laboratory Medicine, of the University of British Columbia, Vancouver, British Columbia, Canada.
Neurogastroenterol Motil ; 34(9): e14368, 2022 09.
Article en En | MEDLINE | ID: mdl-35383423
ABSTRACT

BACKGROUND:

Many of the studies on COVID-19 severity and its associated symptoms focus on hospitalized patients. The aim of this study was to investigate the relationship between acute GI symptoms and COVID-19 severity in a clustering-based approach and to determine the risks and epidemiological features of post-COVID-19 Disorders of Gut-Brain Interaction (DGBI) by including both hospitalized and ambulatory patients.

METHODS:

The study utilized a two-phase Internet-based survey on (1) COVID-19 patients' demographics, comorbidities, symptoms, complications, and hospitalizations and (2) post-COVID-19 DGBI diagnosed according to Rome IV criteria in association with anxiety (GAD-7) and depression (PHQ-9). Statistical analyses included univariate and multivariate tests.

RESULTS:

Five distinct clusters of symptomatic subjects were identified based on the presence of GI symptoms, loss of smell, and chest pain, among 1114 participants who tested positive for SARS-CoV-2. GI symptoms were found to be independent risk factors for severe COVID-19; however, they did not always coincide with other severity-related factors such as age >65 years, diabetes mellitus, and Vitamin D deficiency. Of the 164 subjects with a positive test who participated in Phase-2, 108 (66%) fulfilled the criteria for at least one DGBI. The majority (n = 81; 75%) were new-onset DGBI post-COVID-19. Overall, 86% of subjects with one or more post-COVID-19 DGBI had at least one GI symptom during the acute phase of COVID-19, while 14% did not. Depression (65%), but not anxiety (48%), was significantly more common in those with post-COVID-19 DGBI.

CONCLUSION:

GI symptoms are associated with a severe COVID-19 among survivors. Long-haulers may develop post-COVID-19 DGBI. Psychiatric disorders are common in post-COVID-19 DGBI.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Gastrointestinales / COVID-19 Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Humans Idioma: En Revista: Neurogastroenterol Motil Asunto de la revista: GASTROENTEROLOGIA / NEUROLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Gastrointestinales / COVID-19 Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Humans Idioma: En Revista: Neurogastroenterol Motil Asunto de la revista: GASTROENTEROLOGIA / NEUROLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Canadá